Primary tumor and metastasis in ovarian cancer differ in their content of urokinase-type plasminogen activator, its receptor, and inhibitors types 1 and 2.

@article{Schmalfeldt1995PrimaryTA,
  title={Primary tumor and metastasis in ovarian cancer differ in their content of urokinase-type plasminogen activator, its receptor, and inhibitors types 1 and 2.},
  author={Barbara Schmalfeldt and Walther Christian Kuhn and Ute Reuning and Lothar Pache and Peer Dettmar and Manfred Schmitt and F. J{\"a}nicke and Heinz Hoefler and Henner Graeff},
  journal={Cancer research},
  year={1995},
  volume={55 18},
  pages={3958-63}
}
The relevance of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor (PAI) type 1 in predicting the survival probability of patients with advanced ovarian cancer after radical surgery and adjuvant chemotherapy by assessing the patients' primary tumors has recently been shown by us (W. Kuhn et al., Gynecol. Oncol., 55: 401-409, 1994). In the present study, we determined uPA, uPA receptor, PAI-1, and PAI-2 concentrations in primary tumors and tumor-infiltrated omentum… CONTINUE READING